Doublewin Biological Technology Co., Ltd.(expird)
Free supplier Enterprise Certification
- Free
supplier - 4th
years
Free supplier Enterprise Certification
Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
CAS NO.1165910-22-4
1. We have experience in exporting steroids, as you know, EU places much emphasis on them, and you must find a experienced partner who will assure you;
2. Quality: Our company is a professional leading factory in China in pharmaceutical area, We had stable customers and exported to Germany, Spain, UK, USA, Australia, Middle East, and any other countries. We can provide good references about our company. As for the quality of the products, we 're sure they can satisfy you well enough;
3. Package: Professional packing with professional materials
4. Delivery: We have products in stock, and we will deliver them soon when your PO arrived.
Meanwhile we will give you the tracking number in order to make you know the exact location of the products. We will keep track of the product until they arrive you; We choose the best courier service for you, and with the delivery around 4-7 working days.
5. Service: Best Service with after-sales service and consultation.
Product Name: 4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile(LGD-4033)
Synonyms: 4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile(LGD-4033);LGD-4033;4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)benzonitrile;4-((R)-2-((R)-2,2,2-Trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile
LGD-4033 CAS: 1165910-22-4
LGD-4033 MF: C14H12F6N2O
LGD-4033 MW: 338.2482992
Skype:Wendy.Doublewin
Email:doublewin-wendy@nandrolonesteroid.com
LGD-4033 (now known as VK5211). It is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics It’s in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
How LGD-4033 works
LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.
LGD-4033 Uses
LGD is still fairly new (3-5 years), but the results have been very similar in studies and logs. LGD-4033 has undergone several recent studies and trials to find the best and safest way to use it. From these trials, the results have shown increases in lean body mass and decreases in body fat. There is also a significant increase in strength, well being, as well as healing possibilities.
effects of LGD-4033:
Bulking
LGD has shown the most ability of any SARM to put on size that could be considered a bulk. This will, of course, be dependent upon the diet used. Users that have experienced more than 10lb. increases, and have had a significant increase in calorie intake. The possibility of this type of size is present with LGD use. A recommend dosage for this type of goal would be 5-10 mg day for 8 weeks.
Cutting
LGD can be used to cut as well. It will shine more-so if ran in conjunction with SARMS S-4 and Cardarine (GW-501516). This would be similar to a SARMS triple stack that is normally ran with Ostarine, except there is a possibility of more size being put on while cutting. A good dose for this method would be 3-5 mg a day for 8 weeks.
SARMs
| Name | CAS NO. | Usage |
| AICAR | 2627-69-2 | acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
| MK2866 | 841205-47-8 | medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
| MK-677 | 15972-10-0 | for the treatment of frailty in the elderly |
| LGD-4033 | 1165910-22-4 | pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
| GW1516 | 317318-70-0 | For obesity, diabetes, dyslipidemia and cardiovascular disease |
| Andarine(S4) | 401900-40-0 | partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
| SR9009 | 1379686-30-2 | under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
| RAD140 | 1182367-47-0 | New generation for gaining mass and cutting edges |
| YK11 | 431579-34-9 | YK11: a SARM and myostatin inhibitor in one |
| AC262356 | 870888-46-3 | New SARMS |
| SR9011 | 1379686-29-9 | New SARMS |
| S23 | 1010396-29-8 | New SARMS |
| GW0724 | 317318-84-6 | New SARMS |